KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) EBIT Margin (2016 - 2025)

NovoCure (NVCR) has disclosed EBIT Margin for 12 consecutive years, with 23.17% as the latest value for Q4 2025.

  • Quarterly EBIT Margin rose 1609.0% to 23.17% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 23.47% through Dec 2025, up 470.0% year-over-year, with the annual reading at 23.47% for FY2025, 470.0% up from the prior year.
  • EBIT Margin hit 23.17% in Q4 2025 for NovoCure, down from 21.54% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 0.07% in Q1 2021 to a low of 49.71% in Q2 2023.
  • Historically, EBIT Margin has averaged 24.54% across 5 years, with a median of 22.75% in 2024.
  • Biggest five-year swings in EBIT Margin: tumbled -4872bps in 2023 and later skyrocketed 2738bps in 2024.
  • Year by year, EBIT Margin stood at 17.56% in 2021, then plummeted by -91bps to 33.46% in 2022, then decreased by -16bps to 38.66% in 2023, then dropped by -2bps to 39.25% in 2024, then soared by 41bps to 23.17% in 2025.
  • Business Quant data shows EBIT Margin for NVCR at 23.17% in Q4 2025, 21.54% in Q3 2025, and 24.89% in Q2 2025.